Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03206944|
Recruitment Status : Completed
First Posted : July 2, 2017
Last Update Posted : July 2, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hypertension,Essential Obesity||Drug: acetylsalicylic acid Drug: Tomato Fruit Extract||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||82 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk|
|Actual Study Start Date :||July 1, 2015|
|Actual Primary Completion Date :||January 1, 2017|
|Actual Study Completion Date :||June 1, 2017|
Experimental: Group 1 ASA
Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
Drug: acetylsalicylic acid
Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
Other Name: Group 1 ASA
Experimental: Group 2 STE
Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
Drug: Tomato Fruit Extract
Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
Other Name: Group 2 STE
- Inhibition of platelet function in response to anti-platelet therapy STE and ASA [ Time Frame: 1 month ]The platelet inhibition after STE and ASA therapy (VerifyNow Aspirin for ASA and STE Groups and VerifyNow P2Y12 for STE Group only) The platelet reactivity measurements will be performed using the VerifyNow Tests (Accumetrics Inc., USA) method.
- The reduction in BP after STE therapy [ Time Frame: 1 month ]The reduction in office BP (measured three times in standard conditions) and in 24-hour ABPM parameters
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03206944
|Study Director:||Andrzej Tykarski, Prof||Department oh Hypertension, Angiology and Internal Disease. University of Medical Sciences. Poznan,Poland|